This page shows the latest Q2 results news and features for those working in and with pharma, biotech and healthcare.
The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... One concerning caveat among the otherwise positive results was the decrease in sales for BMS’ immunotherapy Opdivo,
Disruption to uptake of HIV and hepatitis C drugs caused by pandemic
That includes a rise in product sales, with a 6% increase in Q2 to $6.04bn and an 11% increase to $12.36bn for the half year. ... The pharma giant seems to have avoided any significant effects on its earnings in the quarter, compared to other drugmakers
Pharmaceutical sales took a 4% hit in Swiss francs. Swiss pharma Roche is the latest pharma company to be hit in its second quarter results by the COVID-19 pandemic, with ... Roche’s diagnostic division results were a mixed bag, with overall sales
Prior to the results presentation, investors were rocked by the unexpected news that Biogen’s chief financial officer Jeffrey Capello was departing from the company. ... Biogen completed a marketing application for the high-risk Alzheimer’s therapy
The company reported that net income was down 11% to $1.9bn compared with last year’s second quarter results. ... Despite the somewhat marred results, there were some highlights in the Q2 results, including a strong launch for the company’s spinal
More from news
Approximately 13 fully matching, plus 25 partially matching documents found.
Our broad, yet focused, portfolio delivered strong results in Q2, with sales growing 19 per cent. ... Consumer health grew five per cent in Q2, largely due to products like Theraflu and Voltaren.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...